Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages. Seagen claims Enhertu ( ...

Companies like AstraZeneca, Daiichi Sankyo, Pfizer and Merck are learning from previous setbacks in the ADC space to improve ...

Discover which therapies are expected to grab the HER2-low cancers market share @ HER2-low Cancers Market Report The HER2-low ...

PFE's oncology portfolio, boosted by Seagen and late-stage pipeline assets, may fuel growth amid lackluster stock performance ...

In this video, Megan Kruse, MD, breast medical oncologist at Cleveland Clinic, discusses results from an interim analysis of the DESTINY-Breast09 trial, which were presented at ASCO Annual Meeting.The ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

New data shed light on the best strategies for managing patients who develop interstitial lung disease while being treated ...

VANFLYTA (quizartinib) has been approved by Health Canada for use in combination with standard cytarabine and anthracycline ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, North America, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive ...